TB-500 and BPC-157: the healing stack
The BPC-157 and TB-500 combination is the most widely used peptide healing stack in clinical peptide therapy and the community practice that surrounds it. The rationale is mechanistic complementarity: TB-500 provides systemic cell migration support while BPC-157 provides local angiogenesis and tissue-specific repair signaling. Here is how the two peptides work together, the BPC-157 and TB-500 dosage protocols used in practice, the published research supporting each component, and a direct mechanism comparison for choosing one, the other, or both.
Key takeaways
- TB-500 and BPC-157 work through different mechanisms — TB-500 promotes cell migration via actin cytoskeleton remodeling (systemic, intracellular), while BPC-157 promotes angiogenesis and tissue repair via VEGFR2 and growth factor modulation (local, receptor-mediated).
- The stack protocol: 2.5 mg TB-500 + 250–500 mcg BPC-157, twice weekly during a 4–6 week loading phase. BPC-157 is injected near the injury site; TB-500 is injected subcutaneously anywhere.
- Combined, the stack provides both “get repair cells to the injury” (TB-500) and “build the vascular and signaling infrastructure at the injury” (BPC-157) — covering the two rate-limiting steps in tissue healing.
- Pre-mixed BPC-157 TB-500 blend vials are available from some suppliers. Common ratios: 5 mg BPC-157 + 5 mg TB-500 per vial, or 10 mg BPC-157 + 5 mg TB-500.
- In head-to-head comparison (BPC-157 vs TB-500), BPC-157 is better for localized injuries with good blood supply; TB-500 is better for systemic healing support and injuries with poor vascularity. The combination is better than either alone for most injury types.
Why the stack works: mechanism synergy
Tissue healing after injury follows a predictable biological sequence: inflammation, cell migration to the injury site, angiogenesis (new blood vessel formation), extracellular matrix deposition, and tissue remodeling. The two rate-limiting steps in most injuries are getting repair cells to the site and establishing blood supply to feed the repair process. TB-500 addresses the first bottleneck and BPC-157 addresses the second. This is why the BPC-157 and TB-500 stack produces outcomes that exceed either peptide alone — not because of pharmacological synergy at a receptor level, but because they solve different biological problems in the healing cascade.
TB-500 (the LKKTETQ fragment of Thymosin Beta-4) works intracellularly by modulating actin cytoskeleton dynamics. It enhances the speed and directionality of cell migration — fibroblasts, myoblasts, endothelial cells, and immune cells all move faster and more purposefully toward injury sites when TB-500 is present. The effect is systemic: TB-500 injected subcutaneously in the abdomen distributes through tissue compartments and enhances cell migration throughout the body.
BPC-157 (Body Protection Compound, a 15-amino-acid fragment of gastric juice protein BPC) works primarily through receptor-mediated pathways at the local injury site. It upregulates VEGFR2 (vascular endothelial growth factor receptor 2), promoting angiogenesis — the sprouting of new capillaries into the repair zone. It also modulates nitric oxide signaling, growth factor expression, and inflammatory cytokine profiles at the injection site. Unlike TB-500, BPC-157’s effects are most pronounced at and near the site of injection.
BPC-157 and TB-500 dosage protocols
The standard BPC-157 and TB-500 dosage protocol for the healing stack:
| Phase | TB-500 | BPC-157 | Frequency | Duration |
|---|---|---|---|---|
| Loading | 2.5–5 mg | 250–500 mcg | 2×/week | 4–6 weeks |
| Maintenance | 2.5 mg | 250 mcg | 1–2×/week | 4–8 weeks |
| Acute injury (aggressive) | 5 mg | 500 mcg | 2×/week | 4 weeks, then step down |
Injection placement: TB-500 is injected subcutaneously in the abdomen, upper arm, or thigh — location doesn’t matter because the effect is systemic. BPC-157 is injected subcutaneously as close to the injury site as practical — for a patellar tendon injury, inject BPC-157 in the subcutaneous tissue near the knee; for a rotator cuff issue, inject near the shoulder. This localization difference is the key practical distinction in how you administer the stack.
The BPC-157 TB-500 dosage ratio in community practice is typically 1:10 by weight (e.g., 250 mcg BPC-157 to 2.5 mg TB-500, or 500 mcg BPC-157 to 5 mg TB-500). Some practitioners run the BPC-157 and TB-500 dosage at a 1:5 ratio for more BPC-157-dominant protocols when the injury is highly localized and vascular support is the priority.
BPC-157 TB-500 blend vials
Pre-mixed BPC-157 TB-500 blend vials combine both peptides in a single lyophilized powder. Common formulations include 5 mg BPC-157 + 5 mg TB-500 per vial and 10 mg BPC-157 + 5 mg TB-500 per vial. The advantage of blends is convenience — single reconstitution, single injection, simplified protocol. The disadvantage is loss of dosing flexibility and the inability to inject BPC-157 locally near the injury while injecting TB-500 systemically elsewhere. For injuries where localized BPC-157 placement matters (isolated tendon or ligament injuries), separate vials with separate injection sites are preferred. For general healing support, systemic recovery from surgery, or protocols where convenience outweighs localization precision, blends work well.
BPC-157 vs TB-500: head-to-head comparison
| Parameter | TB-500 | BPC-157 |
|---|---|---|
| Primary mechanism | Actin cytoskeleton remodeling / cell migration | VEGFR2 angiogenesis / growth factor modulation |
| Action scope | Systemic (distributes from any injection site) | Primarily local (strongest near injection site) |
| How it enters cells | Intracellular — binds actin directly | Receptor-mediated — signals through VEGFR2 and NO pathways |
| Best for | Large injuries, systemic recovery, poor-vascularity injuries | Localized injuries, tendon/ligament, gut healing |
| Half-life | ~5–6 hours (effects persist longer) | ~10–15 minutes (very short, frequent dosing needed) |
| Typical dose | 2.5–5 mg, 2×/week | 250–500 mcg, 1–2×/day |
| Human trial data | Phase 1 safety trial completed | No published human clinical trial |
| WADA status | Banned (S2) | Not specifically listed (but peptide use may be flagged) |
| FDA status (2026) | Removed from Category 2, not yet on Category 1 | Removed from Category 2 (April 2026) |
When people search BPC-157 vs TB-500 or TB-500 vs BPC-157, the answer is almost always “both” rather than “one or the other.” The peptides address different bottlenecks in the healing cascade. If forced to choose one: BPC-157 for a localized, well-vascularized injury (Achilles tendinopathy, rotator cuff strain, gut permeability); TB-500 for systemic recovery needs, large-area injuries, or injuries in poorly vascularized tissue (avascular necrosis, chronic tendinosis with poor blood supply). But the stack is superior to either alone for virtually all injury types in community practice.
Running the stack: practical protocol
A typical 8-week TB-500 and BPC-157 protocol:
Weeks 1–4 (loading): 2.5 mg TB-500 subcutaneous abdomen, Monday and Thursday. 250–500 mcg BPC-157 subcutaneous near injury site, Monday and Thursday (same days, different syringes, different sites). If the injury is bilateral or systemic, BPC-157 can be injected in the abdomen alongside TB-500.
Weeks 5–8 (maintenance): 2.5 mg TB-500 subcutaneous abdomen, Monday only. 250 mcg BPC-157 near injury site, Monday and Thursday (or daily if aggressive). Taper BPC-157 frequency as symptoms improve.
Week 9+: Discontinue both. Assess healing progress. If needed, repeat the cycle after a 4-week break.
The TB-500 BPC-157 stack for specific injuries
Tendon and ligament injuries
The stack is most popular for tendon and ligament healing. TB-500 gets fibroblasts migrating to the injury; BPC-157 builds the local blood supply to support collagen deposition. For chronic tendinopathy (Achilles, patellar, rotator cuff), the combination of systemic TB-500 with localized BPC-157 injection provides both the cellular supply chain and the vascular infrastructure needed for tissue remodeling.
Post-surgical recovery
Following orthopedic surgery (ACL reconstruction, rotator cuff repair, meniscus repair), the BPC-157 and TB-500 stack is used to accelerate the biological healing timeline. TB-500’s systemic migration effects help mobilize progenitor cells to the surgical site; BPC-157 supports local angiogenesis in the repair tissue.
Muscle injuries
For muscle strains and contusions, TB-500 promotes satellite cell and myoblast migration while reducing fibrotic scarring; BPC-157 enhances local perfusion and modulates inflammatory signaling. The combination aims to reduce scar tissue formation while accelerating functional muscle recovery.
Frequently asked questions
What is the BPC-157 and TB-500 dosage?
Standard stack dosage: 2.5–5 mg TB-500 + 250–500 mcg BPC-157, administered twice weekly during a 4–6 week loading phase, then stepped down to once or twice weekly for maintenance. TB-500 is injected subcutaneously anywhere; BPC-157 is injected near the injury site for maximum local effect.
Is the BPC-157 TB-500 blend better than separate injections?
Separate injections allow you to place BPC-157 near the injury site for localized effect while injecting TB-500 systemically. Blends sacrifice this targeting flexibility for convenience. For highly localized injuries, separate vials are preferred. For general healing support, blends work well.
Can you take BPC-157 and TB-500 together?
Yes — combining BPC-157 and TB-500 is the standard peptide healing stack. They work through completely different mechanisms (local angiogenesis vs. systemic cell migration) and there are no known negative interactions. Most peptide therapy protocols use them simultaneously rather than sequentially.
Which is better, BPC-157 or TB-500?
Neither is universally “better” — they solve different problems. BPC-157 excels at localized healing with strong angiogenic support (tendons, gut, localized inflammation). TB-500 excels at systemic healing support and injuries in poorly vascularized tissue. For most injury types, the combination outperforms either alone.